A live webcast of the presentation will be available on the Events page in the Investors & News section of the Metsera website at investors.metsera.com . A replay of the webcast will be available for ...
Metsera's IPO raised $316.2 million, funding its obesity drug MET-097i, which shows promise with once-monthly dosing. Read ...
Wall Street analysts initiated coverage on Metsera with bullish outlook given the biotech firm’s differentiated obesity drug pipeline and potential for significant upside. Metsera is also viewed as a ...
Metsera’s GLP-1 peptide has a long half-life, meaning it could be administered once a month. The company is ready to scale up ...
Guggenheim has initiated Metsera at buy saying that the biotech's pipeline of injectable and oral nutrient stimulated hormone ...
Guggenheim analyst sees significant upside in Metsera stock to $56. MTSR is working on both injectable and oral weight-loss ...
At the beginning of January, Metsera reported preliminary Phase 2a data showing the drug led to dose-dependent weight loss. At the high dose, the average placebo-adjusted weight loss from the ...
(Reuters) -Shares of weight-loss drug developer Metsera surged nearly 42% in a strong Nasdaq debut on Friday, valuing the ARCH Venture Partners-backed biotech firm at $2.68 billion. The strong market ...
Weight-loss drug developer Metsera has raised $275 million after pricing its U.S. initial public offering at $18 per share, above its targeted range, the ARCH Venture Partners-backed biotech company ...
US-based Metsera has set its sights on a $289m public listing as the weight loss drug developer becomes one of the early biotechs to venture into the thawing IPO landscape in 2025. Metsera is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results